Views
4 years ago

94 - MS Perez de Vargas - Octubre 2015

  • Text
  • Perezdevargas
  • Addictions
  • Impulsividad
  • Adicciones
  • Esquizofrenia
  • Pacientesduales
  • Tratamientopolifarmacologico
  • Nota
  • Psico
  • Clozapina
  • Receptores
  • Sciens
  • Craving
  • Evidencia
  • Olanzapina
  • Editorial
  • Estudios
  • Pacientes
  • Tratamiento
Tratamiento polifarmacológico en pacientes duales de alto riesgo. Parte 2

Dra. María Sol

Dra. María Sol Perez de Vargas edición. Madrid. Grupo Aula Médica SL. 2010. Pág. 223-245. 14. Zorrilla Zubilete, M. “Mecanismos moleculares y vías de señalización en la neurobiología de las adicciones”. En Zorrilla Zubilete, M; ed. Tratado de psicofarmacología y neurociencia. Buenos Aires. Editorial Sciens S.R.L. 2012; Volumen V, Adicciones; Pág. 31-52. 15. Hyman SE, Nestler EJ. Intiation and adaption: a paradigm for understanding psychotropic drug action. American Journal of Psychiatry 1996; 153 (2); 151-162. 16. Nutt, D; et al. Development of a rational scale to assess the harm of drugs of potential misuse. Consultado el: 27 de enero de 2015, en http://www.beckleyfoundation.org/bib/doc /bf/2007_David_211305_1.pdf 17. Bolla KI, Eldreth DA, London ED, Kiehl KA, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, Funderburk FR, Ernst M. Neuroimage. Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task. 2003; 19:1085–1094. 18. Kampman KM, Volpicelli JR, Mulvaney F, Rukstalis M, Alterman AI, Pettinati H, Weinrieb RM, O'Brien CP (2002) Cocaine withdrawal severity and urine toxicology results from treatment entry predict outcome in medication trials for cocaine dependence. En: Kranzler HR; Ciraulo, DA; Zindel, LR. Clinical Manual of Addiction Psychopharmacology. Segunda edición. Arlington. American Psychiatric. 27:251– 260. 19. Spronk, D; Dumont, GJH; Verkes, R; Brujin, ERA. Acute effects of delta 9-tetrahydrocannabinol performance monitoring in healthy volunteers. Fronters in Behavioral Neuroscience. 2011; 5:116-125. 20. Colin N. Haile, CN. Mahoney,JJ III. Newton, TF, De La Garza, R. Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: Focus on dopamine, norepinephrine and glutamate. Consultado el 6 de marzo de 2015, en doi: 10.1016/j.pharmthera.2012.01.010 21. Horger BA, Iyasere CA, Berhow MT, Messer CJ, Nestler EJ, Taylor JR: Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. The Journal of Neuroscience. 1999; 19 (10): 4110-4122. 22. Nestler EJ, Berhow MT, Brodkin ES. . Molecular mechanisms of drug addiction: adaptations in signal trasduction pathways. Journal of Molecular Psychiatry. 1996, (1)190-191. 23. Zieher, LM. Neurobiología de las adicciones y procesos de plasticidad involucrados. En: Zorrilla Zubilete M, ed., Tratado de psicofarmacología y neurociencia. Buenos Aires. Editorial Sciens S.R.L. 2012; Volumen V, Adicciones; Pág. 21-30. 24. Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Current Opinion in Neurobiology. 1997; (7) 713- 719. 25. Kelly,TM; Daley, DC; Douaihy, AB. Treatment of Substance Abusing Patients with Comorbid Psychiatric Disorders. Addict Behav. 2012; 37(1):11-24 26. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. Consultado el: 14 de mayo de 2014, en: http://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/WFB SP_SZ_Guidelines_Part1_2012.pdf 27. Jufe G. Antidepresivos. En: Psicofarmacología Práctica. Primera edición. Buenos Aires: Editorial Polemos; 2012: 36-197. 28. Kurita, M; Holloway, T; Gonzalez Maeso, J. HDAC2 as a new target to improve schizophrenia treatment. Expert Rev Neurother. 2013; 13 (1): 1–3. 29. Suzuki, T; Uchida, H; Takeuchi, H; Nakajima, S; Nomura, k; Tanabe, A. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Human Psychopharmacology Clinical and Experimental. 2009; 24: 628–638. 30. Hugh Myrick, H; Malcolm, R; Anton, R. The Use of Antiepileptics in the Treatment of Addictive Disorders. Consultado el 6 de febrero de 2015, en http://primarypsychiatry.com/the-use-of-antiepileptics-in-thetreatment-of-addictive-disorders/ 31. Blanchard, JJ; Brown, SA; Horan, WP; et al. Substance use disorders in schizophrenia: review, integration and a proposed model. Clinical Psychology Review. 2000; 20. Pág. 207– 234. 32. Kavanagh, DJ; McGrath, J; Saunders, JB;, et al. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002; 62. Pág. 743– 755. 33. Smit, F; Bolier, L; Cuijpers, P. Cannabis use and the risk of later schizophrenia: a review. Addiction. 2004: 99 (4). Pág. 425– 430. 34. Semple, DM; McIntosh, AM; Lawrie, SM. Cannabis as a risk factor for psychosis: systematic review. Journal of Psychopharmacology. 2005; 19. Pág. 187-194. 35. Tsapakis, EM; Guillin, O; Murray, RM. Does dopamine sensitization underlie the association between schizophrenia and drug abuse? Current Opinion in Psychiatry. 2003; 16 (suppl. 2), 45– 52. 36. Jufe G. Ansiolíticos e hipnóticos. En: Psicofarmacología Práctica. Primera edición. Buenos Aires: Editorial Polemos; 2012: 199-279. 37. Jobes, M; Ghitza UE; Epstein, DH; Phillips, KA; Heishman, SJ; Preston, KL. Clonidine blocks stress-induced craving in cocaine users. Psychopharmacology. 2011; 218 (1): 83-88. 38. Botreau, F; Paolone, G; Stewart, J. d- Cycloserine facilitates extinction of a cocaine-induced conditioned place preference. Behavioural Brain Research. 2006; 172. Pág. 173–178. 20 // EDITORIAL SCIENS

Biblioteca

Av. García del Río 2585 Piso 12 A - C.A.B.A
+54 11 2092 1646 | info@sciens.com.ar

Editorial Sciens, Todos los Derechos Reservados 2015